Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial
The LancetPublished 1 April 2002
Timo Erkinjuntti, Alexander Kurz, Serge Gauthier, Roger Bullock, Sean Lilienfeld, C. V. Damaraju
Citations757
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Galantamine showed a therapeutic effect on all key areas of cognitive and non-cognitive abilities in this group of dementia patients and was well tolerated.
Abstract
Galantamine showed a therapeutic effect on all key areas of cognitive and non-cognitive abilities in this group of dementia patients.
Keywords
MedicineNeuroscience
Journal of Psychiatric Research“Mini-mental state”
86,858 Citations1975Marshal F. Folstein, Susan E. Folstein +1 more
A simplified, scored form of the cognitive mental status examination, the “Mini-Mental State” (MMS) which includes eleven questions, requires only 5-10 min to administer, and is therefore practical to use serially and routinely.
NeurologyClinical diagnosis of Alzheimer's disease
27,993 Citations1984Guy M. McKhann, David A. Drachman +4 more
The criteria proposed are intended to serve as a guide for the diagnosis of probable, possible, and definite Alzheimer's disease; these criteria will be revised as more definitive information becomes available.
JNCI Journal of the National Cancer InstituteStatistical Aspects of the Analysis of Data From Retrospective Studies of Disease
14,860 Citations1959Nathan Mantel, William Haenszel
NeurologyVascular dementia
4,855 Citations1993Gustavo C. Román, T. K. Tatemichi +29 more
These criteria for the diagnosis of vascular dementia are intended as a guide for case definition in neuroepidemiologic studies, stratified by levels of certainty (definite, probable, and possible).
American Journal of PsychiatryA new rating scale for Alzheimer's disease
4,123 Citations1984Wilma G. Rosen, Richard C. Mohs +1 more
A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease.
NeurologyThe Neuropsychiatric Inventory
2,040 Citations1997Jeffrey L. Cummings
The NPI is a useful instrument for characterizing the psychopathology of dementia syndromes, investigating the neurobiology of brain disorders with neuropsychiatric manifestations, distinguishing among different dementia syndromees, and assessing the efficacy of treatment.
JAMABrain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
1,579 Citations1997David A. Snowdon
Findings suggest that cerebrovascular disease may play an important role in determining the presence and severity of the clinical symptoms of AD.
NeurologyA 5-month, randomized, placebo-controlled trial of galantamine in AD
923 Citations2000Pierre N. Tariot, Paul R. Solomon +5 more
Slow dose escalation appears to enhance the tolerability of galantamine, minimizing the incidence and severity of adverse events and significantly benefits the cognitive, functional, and behavioral symptoms of AD.
American Journal of Occupational TherapyDevelopment of a Functional Measure for Persons With Alzheimer’s Disease: The Disability Assessment for Dementia
907 Citations1999Isabelle Gélinas, Louise Gauthier +2 more
This instrument may help clinicians and caregivers of the population with Alzheimer's disease make decisions regarding the choice of suitable interventions and was found not to have gender bias.
NeurologyGalantamine in AD
871 Citations2000Murray A. Raskind, Elaine R. Peskind +3 more
Galantamine is effective and safe in AD and significantly improved cognition and global function at 6 months, and cognitive and daily function were maintained for 12 months with the 24 mg/d dose.
PubMedIncidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.
685 Citations2000Laura Fratiglioni, L. J. Launer +8 more
It is confirmed that AD is the most frequent dementing disorder in all ages, and that there is a higher incidence of dementia, specifically AD, in women than men among the very old, and there may be regional differences in dementia incidence.
Alzheimer Disease & Associated DisordersValidity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of Change
652 Citations1997Lara Schneider, Jason T. Olin +8 more
The ADCS-CGIC ratings at 12 months were significantly associated with change on four severity scales, and change ratings were sensitive to dementia severity.
BMJEfficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial
629 Citations2000G K Wilcock, Sean Lilienfeld +1 more
As galantamine slowed the decline of functional ability as well as cognition, its effects are likely to be clinically relevant.
EUR Research Repository (Erasmus University Rotterdam)Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts
564 Citations2000Andréa de Paula Lobo, Launer, LJ (Lenore) +10 more
Alzheimer Disease & Associated DisordersOverlap Between Pathology of Alzheimer Disease and Vascular Dementia
469 Citations1999Raj N. Kalaria, Clive Ballard
Cerebrovascular pathology of AD is evaluated in light of peripheral vascular pathophysiology implicated in the etiopathogenesis of the dementia and pathological findings in relation to genetic influences such as apolipoprotein E that may shed light on the link between AD and VaD are considered.
NeurologyPrevalence and outcomes of vascular cognitive impairment
385 Citations2000Kenneth Rockwood, Carolyn Wentzel +5 more
Birkhäuser Boston eBooksValidity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)
304 Citations1997Lon S. Schneider, Jason T. Olin +8 more
Clinical global impressions of change (CGICs) are important measures of efficacy in clinical trials and have been used extensively as primary outcome criteria in psychopharmacological trials and in early clinical trials for antidementia drugs.
NeurologySensitivity and specificity of newly proposed clinical criteria for possible vascular dementia
251 Citations1997Garry E. Gold, Pantéleimon Giannakopoulos +5 more
Data from this validation study provide valuable information to clinicians and researchers who wish to apply these criteria for possible vascular dementia to the diagnosis of VaD.
Journal of Pharmacology and Experimental TherapeuticsPharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
247 Citations1996Gina M. Bores, Francis P. Huger +9 more
Because of its composite profile, including duration of action, oral therapeutic index and pharmacokinetics, P11149 is considered the better therapeutic candidate for the treatment of Alzheimer's disease.
European Journal of PharmacologyAllosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
218 Citations2000Alfred Maelicke, Edson X. Albuquerque
A novel class of nicotinic acetylcholine receptor ligands which, similar to the action of benzodiazepines on GABA(A) receptors, allosterically potentiate submaximal Nicotinic responses are described, which could have a preventive and corrective action on impaired but still functioningNicotinic neurotransmission.
Alzheimer Disease & Associated DisordersVascular Factors and Alzheimer Disease
178 Citations1999Ingmar Skoog, Raj N. Kalaria +1 more
The implication that prevention or management of peripheral vascular disease may prevent or delay the onset of Alzheimer disease or mixed dementia is supported.
European Journal of NeurologyAn efficacy and safety analysis of Exelon<sup>®</sup> in Alzheimer’s disease patients with concurrent vascular risk factors
162 Citations2000Vinod Kumar, R. Anand +3 more
Rivastigmine is effective in both categories of patients, and those with VRF experience greater clinical benefit (cognition, activities of daily living, and disease severity).
Cerebrovascular DiseasesRethinking Vascular Dementia (Part 1 of 2)
139 Citations2007Timo Erkinjuntti, Vladimir Hachinski
Vascular dementia may be regarded as a syndrome of cognitive impairment resulting from vascular diseases, especially isc cerebral palsy.
CNS DrugsCerebrovascular Dementia
72 Citations1999Timo Erkinjuntti
Critical conceptual questions include what constitutes the cognitive syndrome and what are the vascular causes; these lead to consideration of whether the term ‘vascular dementia’ should be replaced by a milder and broader category of ‘ vascular cognitive impairment’.
Alzheimer Disease & Associated DisordersSubtypes of Vascular Dementia
69 Citations1999Kenneth Rockwood, John Bowler +3 more
The challenge of describing subgroups is particularly important in vascular dementia, which, in contrast to more stereotypic processes affecting cognitive function, is better thought of as several syndromes rather than as a disease.
Journal of NeuropsychiatryUse of Donepezil for Vascular Dementia
56 Citations1999Mario F. Mendez, Fargol L. Younesi +1 more
Eight outpatients with subcortical lesions and mild to moderate cognitive impairment received donepezil for 6 months and caregivers reported improved patient activity, engagement, and self-care.
EUR Research Repository (Erasmus University Rotterdam)Frequency of stroke in Europe: a collaborative study of population-based cohorts
43 Citations2000Antonio Di Carlo, Launer, LJ (Lenore) +6 more
PubMedDiagnosis of vascular dementia and Alzheimer's disease.
37 Citations2001Gustavo C. Román
The current diagnostic criteria for VaD, with or without coexisting Alzheimer's disease, are discussed, in an effort to determine how best to diagnose VaD.
PubMedOutcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease.
18 Citations2001Serge Gauthier, Steven H. Ferris
Assessments of cognitive and global function measures, and assessments of abilities to perform activities of daily living (ADL) must be included as part of the optimal assessment battery in VaD trials, and the best ways of measuring these outcomes are addressed.